Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

The Global Drug Gap

Michael R. Reich
Science
New Series, Vol. 287, No. 5460 (Mar. 17, 2000), pp. 1979-1981
Stable URL: http://www.jstor.org/stable/3074885
Page Count: 3
  • More info
  • Cite this Item
The Global Drug Gap
Preview not available

Abstract

Global inequities in access to pharmaceutical products exist between rich and poor countries because of market and government failures as well as huge income differences. Multiple policies are required to address this global drug gap for three categories of pharmaceutical products: essential drugs, new drugs, and yet-to-be-developed drugs. Policies should combine "push" approaches of financial subsidies to support targeted drug development, "pull" approaches of financial incentives such as market guarantees, and "process" approaches aimed at improved institutional capacity. Constructive solutions are needed that can both protect the incentives for research and development and reduce the inequities of access.

Page Thumbnails

  • Thumbnail: Page 
1979
    1979
  • Thumbnail: Page 
1980
    1980
  • Thumbnail: Page 
1981
    1981